Business Wire

SOVEREN

Share
Soveren Lands Star-Studded $6.5M Seed Round, Including 11 Unicorn Founders, to Fight Privacy Incidents

Today Soveren announced a $6.5M seed round, led by firstminute capital and joined by Northzone, 11 unicorn founders , and a group of global CEOs. The founders of Airbnb, Datadog, MuleSoft, Snyk, and Color invested alongside Sir Richard Branson’s family, the Chairman CEO of Palo Alto Networks, and others.

Soveren is addressing one of the key technology challenges of the decade: privacy and compliance for Engineering teams. Their product provides CTOs, CISOs, and Privacy Engineers with easy-to-use tools to detect and address privacy gaps. The calibre of their seed round speaks to the pedigree of founders, and to the size of the task ahead,” said Spencer Crawley, Co-Founding General Partner of firstminute capital.

Holly Branson, Virgin’s Chief Purpose and Vision Officer said: “At Virgin, our customers mean everything to us and treating them with respect and with world class service is at the core of the entire Virgin ethos. The way we handle their personal information is an important extension of this and something we take very seriously. As a family we are delighted to be investors in Soveren, whose mission and innovative technology will enable many more businesses to become better stewards of personal data.”

10 million companies globally are at risk of violating GDPR and other regulatory obligations because of their failure to detect and resolve privacy incidents and risks. Security software successfully addresses security threats, but has a limited impact on addressing privacy challenges. This is because — unlike other confidential data that can be easily isolated and sealed — personal data is actually meant to be accessed, used, and shared in-day-to-day business operations.

Soveren believes that, if security teaches us anything, privacy has to be embraced by engineering because legal measures alone can’t guarantee compliance. We are already witnessing that Engineering and Security teams in many companies are joining forces with Privacy professionals. However, there is a significant need for purpose-built privacy tools in order to implement continuous and automated privacy incident detection and remediation.

“Privacy is the new Security. Engineering and Security teams demand automated, functional, and easy-to-install privacy solutions as their bandwidth for anything else is severely limited. Soveren provides the much needed simplicity in privacy compliance,” stated Peter Fedchenkov, Founder and Co-CEO of Soveren.

Soveren's technology fills a void in Privacy. It strengthens existing security measures and provides protection from financial and brand damage caused by privacy incidents. Privacy incidents include allowing an undetected API to access personal data or storing personal data in systems which were not designed to keep it safe. These incidents and others are fully preventable with Soveren.

Soveren analyzes real-time data flows inside the company’s infrastructure to discover personal data and detect privacy risks. Soveren is taking the lead on providing CTOs, CISOs, and Privacy Engineers with simple yet effective solutions to resolve privacy incidents via actionable intelligence into the personal data used in day-to-day business operations.

"From my experience working with MuleSoft customers, I saw a clear and pressing need to solve the data usage and risk problem of sprawling datasets, and not knowing what was where and how data got used," said Ross Mason, Founder of MuleSoft and Dig Ventures . "Soveren is taking a unique approach to this. It's built from the ground up to listen, learn and report on data inflight without having to access existing systems or personal data."

Soveren has secured 10 lighthouse customers across software, e-commerce, travel, fintech, and healthcare in North America and Europe.

“Frankly, privacy is no longer a question of just GDPR or CCPA compliance. Privacy incidents damage your brand, growth, and ability to attract capital. With Soveren it just got easier to protect yourself from privacy incidents and risks,” noted Alex Bouaziz, Co-Founder & CEO at Deel.

“The spread of personal data across a company’s applications, services, and APIs has become near impossible to track. Soveren's technological edge results in the ability to easily discover personal data, identify privacy risks, and suggest effective control measures,” noted Sergey Barysiuk, Founder & CTO of PandaDoc.

Soveren’s vision is to facilitate the inevitable shift from privacy statements on paper to privacy as an engineering discipline. “I have always believed that developers will eventually assume responsibility for privacy within organizations. Soveren provides them with the monitoring and control tools to get this job done,” said Guy Podjarny, Founder of Snyk.

Soveren is easy to deploy and free to try. To learn more, visit https://soveren.io/ .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release

OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly

Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release

Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit

Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release

New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc

LTIMindtree Wins Two 2025 AWS Partner Awards at AWS re:Invent4.12.2025 13:45:00 CET | Press release

Recognized as Application Modernization Consulting Partner of the Year and Industry Partner of the Year - Travel and Hospitality winner LTIMindtree [NSE: LTIM, BSE: 540005], a leading global technology consulting and digital solutions provider, announced that it received the AWS 2025 Geography and Global Partner Awards, recognizing leaders around the globe who play key roles in helping clients drive innovation and build solutions on Amazon Web Services (AWS). LTIMindtree has been awarded Application Modernization Consulting Partner of the Year (Global) and Industry Partner of the Year - Travel and Hospitality. At the AWS re:Invent 2025 Partner Awards Gala, partners were recognized for their specialization, innovation, and collaboration, and for evolving business models that enable success on AWS while supporting their customers. LTIMindtree was recognized as: The Industry Partner of the Year - Travel and Hospitality: Recognized as a trusted transformation partner in Travel and Hospital

Stafford Establishes Timberland Continuation Fund at USD 1.2 billion4.12.2025 10:53:00 CET | Press release

This marks Stafford’s second timberland fund at over USD 1 Billion in 2025, backed by strong existing investor support and new capital commitments from global institutional investors Stafford Capital Partners (“Stafford”) today announced it has established a USD 1.2 billion continuation vehicle, the Stafford International Timberland Continuation Fund (The Continuation Fund or The Fund), marking a significant milestone in the firm’s strategic management of its timberland holdings. The Continuation Fund is a "roll-up" of three of Stafford’s existing core timberland funds – Stafford International Timberland funds VI, VII and VIII – into a new perpetual fund that will hold 74 high-quality core timberland assets. The fully-deployed portfolio took Stafford seven years to construct and holds interests in over 6.3m acres of commercial timberland in the USA, New Zealand, Australia and Latin America. This includes a number of assets that are seen as key strategic holdings in these regions where

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye